Sally Wang Liang, JD, MPH
Venture Partner, Viva Bioinnovator (VBI)
Sally Wang Liang JD MPH is a Venture Partner at Viva Bioinnovator (VBI), a global life sciences corporate venture with 90 portfolio companies, majority of which are US-based. She is a Board Director (BoD) of AcuraStem, IpiNovyx, and FuseBio, Board Observer for Arrepath, Riparian, Phenomic AI, Shareholder Representative for LucyTx, i2o and GenHouse, and formally BoD of Deka.
She is also SVP of Business Development, Head of the Global Business Unit at PepLib. She is actively involved in the biotech ecosystem: serving on the SAB of New Equilibrium Bioscience, an investor and advisor of AI Proteins, as Expert-in-Residence and President’s Innovation Challenge Judge at the Harvard iLab, and mentor with MassBIO and Activate-Nucleate.
Previously, she was Entrepreneur-in-Residence at a company involved in in-licensing promising university technology into NewCo. She has substantial operating, business development, and fundraising experience as a serial entrepreneur: as the CEO and Co-founder of an international telemedicine company and as Chief Strategy Officer and EVP of IP and Regulatory of a leading digital therapeutics company. As a lawyer, she practiced pharmaceutical patent litigation and IP licensing at the premier intellectual property firm and clerked for a federal judge. She worked on healthcare policy at the national level at the Food and Drug Administration Office of Policy and the US Senate Health Education Labor Pension Committee Health Office. She began her career as a management consultant at Clarion Healthcare. Sally received an A.B. in Biology from Harvard College, a J.D. from Harvard Law School, and a M.P.H from Harvard T.H. Chan School of Public Health.